

PRESS RELEASE
FOR IMMEDIATE RELEASE

**PHARMANIAGA SUCCESSFULLY INSTALLS
MALAYSIA'S FIRST PRE-FILLED SYRINGE FILLING LINE
AT WORLD'S FIRST HALAL VACCINE PLANT**

SHAH ALAM, 8 FEBRUARY 2023 – Pharmaniaga Berhad (Pharmaniaga), through its wholly-owned subsidiary Pharmaniaga LifeScience Sdn Bhd (PLS) has successfully installed a pre-filled syringe (PFS) filling line, the first of its kind in Malaysia, recently.

The vaccine plant is part of PLS' ongoing expansion plan towards becoming the world's first Halal vaccine manufacturing plant. Besides the PFS filling machine, the plant has also commissioned other PFS packing equipment, including denester, automatic visual inspection (AVI) machine, plunger insertion machine, labelling and 2-in-1 combi unit of washer-steriliser.

Pharmaniaga Group Managing Director, Datuk Zulkarnain Md Eusope said the vaccine plant has been handed over last year in November 2022 and has undergone equipment Factory Acceptance Tests (FATs) for production water system in Sweden for Purified Water, Water for Injection and Pure Steam Generator in January 2023.

"We are pleased to share this latest progress of our vaccine plant and honoured to have Malaysia's first PFS filling line at our EU-certified high-technology plant in Puchong. We have also successfully passed tests to administer vaccine testing equipment targeted to be delivered in the first quarter of this year.

"We target for the vaccine plant's overall completion by third quarter of this year," he said.

Alongside this, Datuk Zulkarnain also shared that PLS's ongoing Halal Insulin Project is presently at 82% to date.

"We are concurrently completing our insulin plant located in the same building for insulin cartridges. The FATs activities for labelling and blister packing machines were completed in December 2022.

"Whereas other FATs activities for insulin such as dispensing booths, washer-steriliser, solution manufacturing system (SMS), cartridge filling line and AVI machine are scheduled to start in February 2023. This Halal insulin plant is targeted to be completed in the fourth quarter of 2023," said Datuk Zulkarnain.

The Halal biopharmaceutical plants are targeted to be commercialised in 2024 for vaccine and in 2025 for insulin.



Datuk Zulkarnain noted that both vaccine and insulin plants are the world's first and nation's effort in line with the Group's strategic growth pillar that would spur the future growth of the Halal biopharmaceutical industry of the nation.

The expansion into the Biopharmaceutical industry has been planned since 2017, even before the onset of the COVID-19 pandemic, with plans to partner with reputable parties for technology transfer.

The Manufacturing Division of Pharmaniaga comprises six manufacturing plants across Malaysia and two in Indonesia which produce a range of products from pharmaceuticals, biopharmaceuticals, over-the-counter (OTC) to nutraceuticals. These include products catering to different therapeutic categories such as cardiovascular, respiratory, gastrointestinal, anti-diabetic, analgesics, anti-infectives, vaccines, insulins and health supplements for the local and international markets.

Pharmaniaga Berhad is the leading pharmaceutical Company of Boustead Holdings Berhad group of companies, and together with Lembaga Tabung Angkatan Tentera, are the major shareholders of the Company.

-END-

About Pharmaniaga Berhad

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of the Company. Listed on the Main Board of Bursa Malaysia, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy. With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and is empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical arena. For more information, please log on to <https://pharmaniaga.com/>

Issued for Pharmaniaga Group by Corporate Communications Department, Pharmaniaga Berhad. For media enquiries, please contact Dato' Najmuddin Abdullah at 019-3387777, email, najmuddin@pharmaniaga.com or Dato' Zuhri Iskandar Kamarzaman at 03-3342 9999 ext 434 or email zuhri@pharmaniaga.com.